Manifestations of the carcinoid syndrome include the "classic" triad of cutaneous flushing, diarrhea, and valvular heart disease and, less commonly, telangiectases, wheezing, and hypotension.

THE patient with the malignant carcinoid syndrome is confronted with a group of uncomfortable and debilitating symptoms. These may include recurrent acute flushing, colicky abdominal pains ...

IGF-1 is the primary biomarker endocrinologists use to manage acromegaly patients. Results from the Phase 2 study in carcinoid syndrome will provide an opportunity for paltusotine to potentially ...

Neuroendocrine tumors (NETs) develop from neurosecretory cells affecting organs like the gastrointestinal tract and lungs.

Diagnosis. Carcinoid tumor of midgut origin with large segment 3 liver metastasis. Carcinoid syndrome and carcinoid heart disease. Management. Symptomatic relief with somatostatin analog therapy ...

The onset of so-called carcinoid syndrome, which develops in approximately 13% of patients who have bronchial carcinoid tumors, is caused by secretion of 5-hydroxytryptamine, histamine or ...

Carcinoid syndrome, a rare but important malignant cause of flushing, should also be considered. Table 1 lists other potential causes of facial flushing. Our patient reported decreased facial ...

Beyond acromegaly treatment, the company is expanding its scope to include a Phase 3 trial for carcinoid syndrome and is reporting additional Phase 2 data for other drug candidates, such as atumelnant ...

These groups include people who are undernourished due to conditions like anorexia, AIDS, and inflammatory bowel disease (IBD ...

Some NETs make large amounts of hormones and proteins that are released into the bloodstream. This can cause a collection of symptoms called carcinoid syndrome. Surgery is often the only treatment you ...

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on September 10, 2024, the Compensation Committee of ...

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) ...